Anti-TNF-α treatment: A possible promoter in endogenous uveitis observational report on six patients: Occurrence of uveitis following etanercept treatment

Current Eye Research

Volumn 35, Issue 8, 2010, Pages 751-756

  Kakkassery, Vinodh ^a   Mergler, Stefan ^a   Pleyer, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anti TNF ; Arthritis; Etanercept; Infliximab; Uveitis

Indexed keywords

CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; ADULT ONSET STILL DISEASE; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL; PSORIASIS; REMISSION; RETINA MACULA EDEMA; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; ARTHRITIS, JUVENILE; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; MIDDLE AGED; PATHOPHYSIOLOGY; SPONDYLITIS, ANKYLOSING; STILL'S DISEASE, ADULT-ONSET; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; STILL'S DISEASE, ADULT-ONSET; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; VISUAL ACUITY; YOUNG ADULT; ARTHRITIS, JUVENILE;

EID: 77955167490     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2010.486520     Document Type: Article

References (28)

1. Reeves SW, Sloan FA, Lee PP, et al. Uveitis in the elderly: Epidemiological data from the National Long-Term Care Survey Medicare Cohort. Ophthalmology. 2006;113:307.
2. Shen DF, Chang MA, Matteson DM, et al. Biphasic ocular inflammatory response to endotoxin-induced uveitis in the mouse. Arch Ophthalmol. 2000;118:521-527.
3. Moreland LW. Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1998;24:579-591.
4. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141-147.
5. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2005;44:1008-1011.
6. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56:3248-3252.
7. Kaipiainen-Seppanen O, Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumor necrosis factor alpha inhibitors. Ann Rheum Dis. 2003;62:88-89.
8. Cobo-Ibanez T, Del Carmen OM, Munoz-Fernandez S, et al. (2008). Do TNF-blockers reduce or induce uveitis? Oxford: Rheumatology. 47:731-741.
9. Reeves SW, Sloan FA, Lee PP, et al. Uveitis in the elderly: Epidemiological data from the National Long-Term Care Survey Medicare Cohort. Ophthalmology. 2006;113:307.
10. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509-516.
11. Okada AA, Sakai J, Usui M, et al. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm. 1998;6:111-120. (Pubitemid 28380075)
12. Fleisher LN, Ferrell JB, McGahan MC. Ocular inflammatory effects of intravitreally injected tumor necrosis factor-alpha and endotoxin. Inflammation. 1990;14:325-335.
13. Rosenbaum JT, Howes EL Jr, Rubin RM, et al. Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. Am J Pathol. 1988;133:47-53.
14. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121:437-440.
15. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45:252-257.
16. Perez-Guijo V, Santos-Lacomba M, Sanchez-Hernandez M, et al. Tumor necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: The involvement of HLA-B27. Curr Med Res Opin. 2004;20: 155-157.
17. Kasner L, Chan CC, Whitcup SM, et al. The paradoxical effect of tumor necrosis factor alpha (TNF-alpha) in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 1993;34:2911-2917.
18. Okamoto S, Streilein JW. Role of inflammatory cytokines in induction of anterior chamber-associated immune deviation. Ocul Immunol Inflamm. 1998;6:1-11.
19. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53: 18-23.
20. Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye (Lond). 2009;23:1868-1870.
21. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California: The Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111:491-500.
22. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol. 2003;87:925.
23. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. J Dermatolog Treat. 2009;20: 100-108.
24. Yazisiz V, Avci AB, Erbasan F, et al. Development of Crohns disease following anti-tumor necrosis factor therapy (etanercept). Colorectal Dis. 2008;10:953-954.
25. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411-452.
26. Li X, Qin J. Modulation of Toll-interleukin 1 receptor mediated signaling. J Mol Med. 2005;83:258-266.
27. Ranganathan P. Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics. 2005;6:481-490.
28. El-Shabrawi Y, Wegscheider BJ, Weger M, et al. Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27-associated uveitis: Association with susceptibility and clinical manifestations. Ophthalmology. 2006;113:695-700.